Cardiac sarcoidosis and giant cell myocarditis after COVID‐19 infection

Abstract

Abstract Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID‐19 infection might suggest that COVID‐19 could be a trigger for granulomatous myocarditis.

Keywords

• Cardiac sarcoidosis
• Giant cell myocarditis
• COVID‐19
• Heart failure